Pharmaceutical company
Sanofi has seen a mix of successes and setbacks recently. Results from their phase 3 trial of RSV vaccine for toddlers proved disappointing, leading to the discontinuation of the project. This setback was compounded by a dip in vaccine sales, attributed to public mistrust. Despite these setbacks,
Sanofi's earnings received a boost from the strong sales of
Dupixent and other new drugs. The company's Q3 profits beat forecasts, offsetting the decline in vaccine sales, and promising growth is expected in FY26. A collaboration with
Evoq is set to bring in next-gen autoimmune tech and a partnership with
Medidia is focused on fast-tracking the development of new therapies. The company made further strides in the AI domain, investing $625m in
Sanofi Ventures. However, the company is under investigation by the European Commission concerning vaccines, and was ordered by a French court to pay a hefty fine due to anti-competitive behavior
Sanofi News Analytics from Thu, 03 Apr 2025 20:10:10 GMT to Sat, 25 Oct 2025 05:20:46 GMT -
Rating 6
- Innovation 5
- Information 8
- Rumor -1
